The company expects its five-marker LucentAD Complete test to offer higher performance than single-marker assay and to secure higher reimbursement.
In the wake of suspending guidance to review the business in the first quarter of the year, QuidelOrtho has restructured and resumed offering a financial outlook.
The research team looked at cell-free DNA fragmentation profiles across the genome combined with measurements of two key biomarkers to detect ovarian cancer.
Investigators found that they could increase CNS infection diagnoses by using metagenomic next-generation sequencing to test cerebrospinal fluid samples.
Centogene to Sell Business to Private Equity Group for €8.7M, Liquidate Remaining Subsidiaries
Charme Capital Partners will acquire complete ownership of Centogene GmbH and will assume Centogene's loan from Oxford Finance.
The firm's Q3 2024 revenues rose 33 percent year over year as both its genomics and data and services revenues increased in the double-digit percent range.